Inspiremd Inc (NSPR)

$1.84 +0.03 (1.66%)
Market Cap 76.69M
Revenue (ttm) 7.01M
Net Income (ttm) -32.01M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -456.63%
Debt to Equity Ratio 0.00
Volume 5,400
Avg Vol 117,752
Day's Range N/A - N/A
Shares Out 42.37M
Stochastic %K 37%
Beta 0.72
Analysts Strong Sell
Price Target $4.50

Company Profile

InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery and other vascular diseases in Europe, Latin America, the Middle East, and the Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard neuroprotection system for transcarotid access and neuro protection, as w...

Industry: Medical Devices
Sector: Healthcare
Phone: 888 776 6804
Address:
6303 Waterford District Drive, Suite 215, Miami, United States
Jackedtothetits42
Jackedtothetits42 Jan. 8 at 4:15 PM
$NSPR 89 volume… that’s it. Almost 2 hours. Disgusting.
0 · Reply
JBinLB
JBinLB Jan. 7 at 8:13 PM
$NSPR she’s a beauty
0 · Reply
RedDogSailor
RedDogSailor Jan. 6 at 8:45 PM
$NSPR Pathetic management.
0 · Reply
JBinLB
JBinLB Jan. 6 at 12:59 PM
$GEVO $NSPR while your money has rotted and depreciated over the last 5+ years in these 2 stagnant ponds, check out what hot stocks have been doing.. $ZETA $ONDS $NBIS
1 · Reply
JBinLB
JBinLB Jan. 5 at 3:59 PM
$NSPR took my loss and finally sold this absolute waste of time. But don’t worry I’ll be back once in a while to bash and warn others to stay away
1 · Reply
JBinLB
JBinLB Jan. 5 at 2:46 PM
$NSPR
0 · Reply
streetlove92
streetlove92 Jan. 5 at 11:54 AM
$NSPR common, do something
1 · Reply
JBinLB
JBinLB Jan. 2 at 5:42 PM
$NSPR down 70% over last 5 years. Jump in, the pond is warm and stagnant
0 · Reply
arcuy
arcuy Dec. 31 at 9:43 PM
$NSPR this is the best way to end 2025, with this company in ATH! Oh... wait a minute...
0 · Reply
jensen146
jensen146 Dec. 31 at 5:27 PM
$NSPR I have held NSPR for Three years. It closed last (2024) at $2.63, and 2023 at $2.81. Not real good progress.
1 · Reply
Latest News on NSPR
Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting

Nov 24, 2025, 7:30 AM EST - 6 weeks ago

Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 21, 2025, 9:00 AM EST - 6 weeks ago

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

InspireMD to Participate in Upcoming Piper Sandler 37th Annual Healthcare Conference

Nov 19, 2025, 4:42 PM EST - 7 weeks ago

InspireMD to Participate in Upcoming Piper Sandler 37th Annual Healthcare Conference

InspireMD, Inc. (NSPR) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 1:06 PM EST - 2 months ago

InspireMD, Inc. (NSPR) Q3 2025 Earnings Call Transcript

InspireMD Reports Third Quarter 2025 Financial Results

Nov 4, 2025, 7:00 AM EST - 2 months ago

InspireMD Reports Third Quarter 2025 Financial Results

InspireMD Names Peter A. Soukas, M.D.

Nov 3, 2025, 7:30 AM EST - 2 months ago

InspireMD Names Peter A. Soukas, M.D.

InspireMD to Announce Third Quarter 2025 Financial Results

Oct 21, 2025, 4:05 PM EDT - 2 months ago

InspireMD to Announce Third Quarter 2025 Financial Results

InspireMD Announces the Appointment of Dan Dearen to its Board of Directors

Sep 17, 2025, 8:00 AM EDT - 4 months ago

InspireMD Announces the Appointment of Dan Dearen to its Board of Directors

InspireMD to Present at Upcoming H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 9:00 AM EDT - 4 months ago

InspireMD to Present at Upcoming H.C. Wainwright 27th Annual Global Investment Conference

InspireMD, Inc. (NSPR) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 12:30 PM EDT - 5 months ago

InspireMD, Inc. (NSPR) Q2 2025 Earnings Call Transcript

InspireMD Reports Second Quarter 2025 Financial Results

Aug 5, 2025, 8:00 AM EDT - 5 months ago

InspireMD Reports Second Quarter 2025 Financial Results

InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors

Jul 31, 2025, 8:31 AM EDT - 5 months ago

InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors

InspireMD Announces Combined Financings of $58 Million

Jul 31, 2025, 8:30 AM EDT - 5 months ago

InspireMD Announces Combined Financings of $58 Million

InspireMD to Announce Second Quarter 2025 Financial Results

Jul 22, 2025, 7:00 AM EDT - 6 months ago

InspireMD to Announce Second Quarter 2025 Financial Results

InspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid Stent System for the Prevention of Stroke

Jul 9, 2025, 7:00 AM EDT - 6 months ago

InspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid Stent System for the Prevention of Stroke

InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke

Jun 24, 2025, 4:05 PM EDT - 7 months ago

InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke

InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke

Jun 13, 2025, 9:00 AM EDT - 7 months ago

InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke

InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer

Jun 3, 2025, 4:05 PM EDT - 7 months ago

InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer

InspireMD, Inc. (NSPR) Q1 2025 Earnings Call Transcript

May 9, 2025, 12:07 PM EDT - 8 months ago

InspireMD, Inc. (NSPR) Q1 2025 Earnings Call Transcript

InspireMD Reports First Quarter 2025 Financial Results

May 9, 2025, 7:00 AM EDT - 8 months ago

InspireMD Reports First Quarter 2025 Financial Results

InspireMD to Present at Upcoming Bank of America 2025 Healthcare Conference

Apr 30, 2025, 9:00 AM EDT - 9 months ago

InspireMD to Present at Upcoming Bank of America 2025 Healthcare Conference

InspireMD to Announce First Quarter 2025 Financial Results

Apr 25, 2025, 9:00 AM EDT - 9 months ago

InspireMD to Announce First Quarter 2025 Financial Results

InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference

Mar 26, 2025, 9:00 AM EDT - 10 months ago

InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference

InspireMD, Inc. (NSPR) Q4 2024 Earnings Call Transcript

Mar 12, 2025, 1:53 PM EDT - 10 months ago

InspireMD, Inc. (NSPR) Q4 2024 Earnings Call Transcript

InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 12, 2025, 7:00 AM EDT - 10 months ago

InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results

InspireMD to Announce Fourth Quarter and Full Year 2024 Financial Results

Feb 26, 2025, 8:00 AM EST - 11 months ago

InspireMD to Announce Fourth Quarter and Full Year 2024 Financial Results

InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime™ 80 cm Carotid Stent System for Use in TCAR procedures

Feb 13, 2025, 7:00 AM EST - 11 months ago

InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime™ 80 cm Carotid Stent System for Use in TCAR procedures

InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)

Dec 9, 2024, 7:00 AM EST - 1 year ago

InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)

InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors

Nov 25, 2024, 4:05 PM EST - 1 year ago

InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors

InspireMD, Inc. (NSPR) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 10:20 AM EST - 1 year ago

InspireMD, Inc. (NSPR) Q3 2024 Earnings Call Transcript

InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System

Oct 15, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System

InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System

Oct 7, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System

InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System

Sep 16, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System

InspireMD, Inc. (NSPR) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 8:58 AM EDT - 1 year ago

InspireMD, Inc. (NSPR) Q2 2024 Earnings Call Transcript

InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 6, 2024, 8:09 AM EDT - 1 year ago

InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update

InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment

Aug 5, 2024, 7:00 AM EDT - 1 year ago

InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment

InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th

Jul 30, 2024, 7:00 AM EDT - 1 year ago

InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th

InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024

May 28, 2024, 8:53 AM EDT - 1 year ago

InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024

InspireMD Inc. (NSPR) Q1 2024 Earnings Call Transcript

May 14, 2024, 10:50 AM EDT - 1 year ago

InspireMD Inc. (NSPR) Q1 2024 Earnings Call Transcript

InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update

May 14, 2024, 7:00 AM EDT - 1 year ago

InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update

InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th

May 7, 2024, 7:00 AM EDT - 1 year ago

InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th

InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference

Apr 3, 2024, 8:59 AM EDT - 1 year ago

InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference

InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024

Mar 26, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024

InspireMD Inc. (NSPR) Q4 2023 Earnings Call Transcript

Mar 6, 2024, 11:30 AM EST - 2 years ago

InspireMD Inc. (NSPR) Q4 2023 Earnings Call Transcript

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Mar 6, 2024, 7:00 AM EST - 2 years ago

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th

Feb 28, 2024, 7:00 AM EST - 2 years ago

InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th

InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System

Feb 12, 2024, 7:00 AM EST - 2 years ago

InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System

InspireMD Receives CE Mark Recertification Under EU's New Medical Device Regulation (MDR) Regulatory Framework

Jan 31, 2024, 7:00 AM EST - 2 years ago

InspireMD Receives CE Mark Recertification Under EU's New Medical Device Regulation (MDR) Regulatory Framework

InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America

Jan 3, 2024, 7:00 AM EST - 2 years ago

InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America

InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System

Dec 20, 2023, 7:00 AM EST - 2 years ago

InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System

Jackedtothetits42
Jackedtothetits42 Jan. 8 at 4:15 PM
$NSPR 89 volume… that’s it. Almost 2 hours. Disgusting.
0 · Reply
JBinLB
JBinLB Jan. 7 at 8:13 PM
$NSPR she’s a beauty
0 · Reply
RedDogSailor
RedDogSailor Jan. 6 at 8:45 PM
$NSPR Pathetic management.
0 · Reply
JBinLB
JBinLB Jan. 6 at 12:59 PM
$GEVO $NSPR while your money has rotted and depreciated over the last 5+ years in these 2 stagnant ponds, check out what hot stocks have been doing.. $ZETA $ONDS $NBIS
1 · Reply
JBinLB
JBinLB Jan. 5 at 3:59 PM
$NSPR took my loss and finally sold this absolute waste of time. But don’t worry I’ll be back once in a while to bash and warn others to stay away
1 · Reply
JBinLB
JBinLB Jan. 5 at 2:46 PM
$NSPR
0 · Reply
streetlove92
streetlove92 Jan. 5 at 11:54 AM
$NSPR common, do something
1 · Reply
JBinLB
JBinLB Jan. 2 at 5:42 PM
$NSPR down 70% over last 5 years. Jump in, the pond is warm and stagnant
0 · Reply
arcuy
arcuy Dec. 31 at 9:43 PM
$NSPR this is the best way to end 2025, with this company in ATH! Oh... wait a minute...
0 · Reply
jensen146
jensen146 Dec. 31 at 5:27 PM
$NSPR I have held NSPR for Three years. It closed last (2024) at $2.63, and 2023 at $2.81. Not real good progress.
1 · Reply
topstockalerts
topstockalerts Dec. 26 at 9:38 PM
After Hours Top Gainers $MB $KXIN $NSPR $SOPA $SKK
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 26 at 7:32 PM
$NSPR RSI: 58.18, MACD: 0.0125 Vol: 0.08, MA20: 1.96, MA50: 2.03 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
TCellTrader
TCellTrader Dec. 25 at 12:07 PM
$NSPR The opportunity set remains meaningful, but only if discipline keeps pace with ambition. The company must show that scale translates into durable margins rather than fragility. Aligned incentives and governance can stabilize expectations. From here, delivery cadence—not ambition—will define investability.
2 · Reply
SuperGreenToday
SuperGreenToday Dec. 25 at 12:52 AM
$NSPR Share Price: $2.05 Contract Selected: May 15, 2026 $2.5 Calls Buy Zone: $0.19 – $0.24 Target Zone: $0.36 – $0.44 Potential Upside: 77% ROI Time to Expiration: 141 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 24 at 11:12 AM
$NSPR Current Stock Price: $2.13 Contracts to trade: $2.5 NSPR Feb 20 2026 Call Entry: $0.14 Exit: $0.26 ROI: 96% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
JBinLB
JBinLB Dec. 23 at 9:15 PM
$NSPR good to see this little dung beetle 🪲 creeping back up
0 · Reply
woodstockery
woodstockery Dec. 22 at 10:08 PM
$NSPR now do a 10x
0 · Reply
arcuy
arcuy Dec. 22 at 5:30 PM
$NSPR so... when?
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 19 at 10:02 AM
$NSPR Current Stock Price: $2.00 Contracts to trade: $2.5 NSPR Dec 19 2025 Call Entry: $0.09 Exit: $0.17 ROI: 90% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
DocRosen
DocRosen Dec. 18 at 3:40 PM
$NSPR
0 · Reply
TrkDvr
TrkDvr Dec. 16 at 3:04 PM
$NSPR I've been in this stock way too long but learned a lot about the medical device trading market. Big mistake to get in early. Only relief I see is a buyout.
1 · Reply